School of Pharmacy, International Medical University, 126, Jalan Jalil Perkasa, Bukit Jalil, Kuala Lumpur, Malaysia.
School of Pharmacy, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia.
Angiogenesis. 2023 Nov;26(4):481-483. doi: 10.1007/s10456-023-09889-2. Epub 2023 Aug 2.
Imatinib, an ABL tyrosine-kinase inhibitor, shows promise in restoring endothelial barrier function in patients with COVID-19, thus, preventing cytokine leakage from the alveolar compartment to the systemic compartment. COVID-19 is characterized by an alveolar cytokine storm, and imatinib has been shown to strengthen the endothelial barrier and mitigate alveolar inflammatory responses by modulating NF-κB signaling. Incorporating imatinib into COVID-19 treatment strategies offers a novel approach to safeguard the endothelial barrier and address the complex pathophysiology of the disease, including its potential implications in long COVID. Given that endothelial dysfunction plays a central role in COVID-19 progression and long COVID development, protecting the endothelial barrier during acute infection is crucial in preventing the persistent endothelial dysfunction associated with long COVID.
伊马替尼是一种 ABL 酪氨酸激酶抑制剂，它在恢复 COVID-19 患者的内皮屏障功能方面显示出前景，从而防止细胞因子从肺泡隔漏入全身隔室。COVID-19 的特征是肺泡细胞因子风暴，伊马替尼已被证明通过调节 NF-κB 信号来增强内皮屏障并减轻肺泡炎症反应。将伊马替尼纳入 COVID-19 治疗策略为保护内皮屏障和解决疾病的复杂病理生理学提供了一种新方法，包括其在长 COVID 中的潜在影响。鉴于内皮功能障碍在 COVID-19 进展和长 COVID 发展中起核心作用，在急性感染期间保护内皮屏障对于预防与长 COVID 相关的持续内皮功能障碍至关重要。
